Project Grant R43HL137525

Federal Project Grant Award Summary Emprime Therapeutics Inc. received a $314,363 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 15, 2025, with a completion date of August 31, 2026. The award funds development of a novel dual adeno-associated virus (AAV) vector technology called STITCHR to enable full-length Factor VIII (FVIII) gene replacement therapy for hemophilia A. Current...

Vesteck, Inc. received a $1,364,080 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 15, 2025, through May 31, 2027. The award supports development and commercialization of an endovascular suturing device designed to augment endograft fixation during endovascular repair of abdominal aortic aneurysm (AAA). The device addresses a critical clinical need by reducing reinterventions...

The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $299,518 Project Grant under the Drug Abuse and Addiction Research Programs (CFDA 93.279) to V-Flow Medical Inc. to develop a novel diagnostic catheter and modular stent system to treat pelvic venous insufficiency (PVI), a primary cause of chronic pelvic pain (CPP) in women. The project will utilize an ovine model to evaluate the safety and efficacy of V-Flow's catheter and stent system in improving clinical outcomes...

The National Center for Advancing Translational Sciences (NCATS), under CFDA Program 93.350, has awarded a $331,034 Project Grant to Vector Surgical LLC to develop the Gene Therapy Catheter (GTC) - an electrical pulsing device designed to enhance the delivery of adeno-associated virus (AAV) gene therapy to the liver. The GTC aims to improve the efficiency and safety of liver-directed gene therapies by combining local delivery with electrical pulsing and a double-balloon system to isolate the...

Federal Grant Award Summary Vanderbilt University received a $489,644 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 1, 2025, with completion targeted for July 31, 2027. The project aims to develop novel drug-coated balloon (DCB) therapies using peptide-based delivery mechanisms to improve long-term vessel patency following angioplasty in peripheral arterial disease (PAD) treatment....

This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports a $560,000 research initiative led by Baylor College of Medicine to develop a "triple gene therapy" treatment for ischemic heart failure. The goal is to leverage a combination of three experimental approaches - inducing cardiomyocyte proliferation, direct cardiac reprogramming of fibroblasts, and increasing angiogenesis - to synergistically regenerate...

This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant of $275,000 awarded to Xtract Medical Inc. aims to develop and demonstrate the feasibility of a novel catheter-based system for improved removal of blood clots during mechanical thrombectomy procedures to treat venous thromboembolism (VTE). The proposed system is designed to effectively remove large blood clots while minimizing damage to blood vessels and reducing complications such as...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $306,870 to Kinetiq Therapeutics LLC, a life science startup in Texas, to conduct proof-of-concept studies on an enzyme replacement therapy (ERT) for Fanconi anemia. Fanconi anemia is a rare inherited disease characterized by bone marrow failure and malignancies. The project aims to demonstrate the feasibility of using an...

Federal Grant Award Summary Washington University's Office of Sponsored Research Services received a $497,998 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded July 1, 2025, with completion targeted for June 30, 2028. The research project, "Elucidating Anti-Angiogenic Tyrosine Kinase Inhibitor-Induced Vascular Dysfunction," addresses a critical gap in understanding cardiovascular...

This $408,599 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate the role of the TGF-beta/SMAD3 pathway in endothelial damage and cardiac remodeling caused by doxorubicin chemotherapy. The research aims to assess how doxorubicin-induced endothelial reprogramming via this pathway contributes to the development of cardiomyopathy, and whether suppressing SMAD3...